CST6 and Miyoshi myopathy: In summary, this work presents a rational approach to engineering BCMA–CST6–CAR-T cells that can effectively target MM tumor cells in vitro and in vivo and that can release large amounts of CST6 protein, which significantly suppresses osteolytic lesions in MM (Figure 8).